Table of Content

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview
4.1. Introduction
4.2. Immune Checkpoint Inhibitors for Lung Cancer Market, by Region

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. High prevalence of lung cancer necessitating immune checkpoint inhibitors
5.1.1.2. Government investment in cancer research and treatment
5.1.1.3. Increasing product approval by regulatory agencies
5.1.2. Restraints
5.1.2.1. Limited affordability and reimbursement for immune checkpoint inhibitor therapies
5.1.3. Opportunities
5.1.3.1. Development of promising predictive biomarkers for immune checkpoint inhibitor therapies
5.1.3.2. Combination of immune checkpoint inhibitors with other cancer therapies
5.1.4. Challenges
5.1.4.1. Lack of research standardization of checkpoint inhibitors
5.1.4.2. Possible side-effects of immune checkpoint inhibitors
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Immune Checkpoint Inhibitors for Lung Cancer Market, by Products
6.1. Introduction
6.2. Atezolizumab
6.3. Durvalumab
6.4. Nivolumab
6.5. Pembrolizumab

7. Immune Checkpoint Inhibitors for Lung Cancer Market, by Type
7.1. Introduction
7.2. CTLA-4 Inhibitors
7.3. PD-1 Inhibitors
7.4. PD-L1 Inhibitors

8. Immune Checkpoint Inhibitors for Lung Cancer Market, by End-Users
8.1. Introduction
8.2. Academic & Research Institutes
8.3. Hospitals
8.4. Pharmaceutical & Biotechnology Companies

9. Americas Immune Checkpoint Inhibitors for Lung Cancer Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Immune Checkpoint Inhibitors for Lung Cancer Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Immune Checkpoint Inhibitors for Lung Cancer Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. AbbVie Inc.
13.1.2. AstraZeneca PLC
13.1.3. Bayer AG
13.1.4. BeyondSpring Pharmaceuticals Inc.
13.1.5. BioLineRx Ltd.
13.1.6. Bristol-Myers Squibb Company
13.1.7. F. Hoffmann-La Roche Ltd.
13.1.8. Genentech, Inc.
13.1.9. GlaxoSmithKline PLC
13.1.10. IQVIA Inc.
13.1.11. Jazz Pharmaceuticals PLC
13.1.12. Laboratory Corporation of America Holdings
13.1.13. Merck KGaA
13.1.14. Mirati Therapeutics Inc.
13.1.15. Ono Pharmaceutical Co., Ltd.
13.2. Key Product Portfolio

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing



List of Figures

FIGURE 1. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET RESEARCH PROCESS
FIGURE 2. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2023 VS 2030
FIGURE 3. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET DYNAMICS
FIGURE 7. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2023 VS 2030 (%)
FIGURE 8. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 10. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
FIGURE 12. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018–2023
TABLE 3. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 6. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DURVALUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 11. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 15. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 19. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 20. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 22. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 23. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 24. ARGENTINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 25. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 26. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 27. BRAZIL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 28. CANADA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 29. CANADA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 30. CANADA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 31. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 32. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 33. MEXICO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 35. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 36. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 37. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 38. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 39. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 40. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 41. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 42. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 43. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 44. AUSTRALIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 45. CHINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 46. CHINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 47. CHINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 48. INDIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 49. INDIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 50. INDIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 51. INDONESIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 52. INDONESIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 53. INDONESIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 54. JAPAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 55. JAPAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 56. JAPAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 57. MALAYSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 58. MALAYSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 59. MALAYSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 60. PHILIPPINES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 61. PHILIPPINES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 62. PHILIPPINES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 63. SINGAPORE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 64. SINGAPORE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 65. SINGAPORE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 66. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 67. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 68. SOUTH KOREA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 69. TAIWAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 70. TAIWAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 71. TAIWAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 72. THAILAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 73. THAILAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 74. THAILAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 75. VIETNAM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 76. VIETNAM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 77. VIETNAM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 82. DENMARK IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 83. DENMARK IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 84. DENMARK IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 85. EGYPT IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 86. EGYPT IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 87. EGYPT IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 88. FINLAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 89. FINLAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 90. FINLAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 91. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 92. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 93. FRANCE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 94. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 95. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 96. GERMANY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 97. ISRAEL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 98. ISRAEL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 99. ISRAEL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 100. ITALY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 101. ITALY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 102. ITALY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 103. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 104. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 105. NETHERLANDS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 106. NIGERIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 107. NIGERIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 108. NIGERIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 109. NORWAY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 110. NORWAY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 111. NORWAY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 112. POLAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 113. POLAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 114. POLAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 115. QATAR IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 116. QATAR IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 117. QATAR IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 118. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 119. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 120. RUSSIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 121. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 122. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 123. SAUDI ARABIA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 124. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 125. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 126. SOUTH AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 127. SPAIN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 128. SPAIN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 129. SPAIN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 130. SWEDEN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 131. SWEDEN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 132. SWEDEN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 133. SWITZERLAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 134. SWITZERLAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 135. SWITZERLAND IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 136. TURKEY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 137. TURKEY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 138. TURKEY IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 139. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 140. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 141. UNITED ARAB EMIRATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 142. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PRODUCTS, 2018-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
TABLE 145. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 146. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SHARE, BY KEY PLAYER, 2023
TABLE 147. IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET LICENSE & PRICING